Obstetrical APS: Is there a place for additional treatment to aspirin-heparin combination?

• Published in: Gynécologie, obstétrique, fertilité & sénologie obstétrique, fertilité & sénologie, 2017-01, Vol.45 (1), p.37-42
• Main Authors: Mekinian, A, Kayem, G, Cohen, J, Carbillon, L, Abisror, N, Josselin-Mahr, L, Bornes, M, Fain, O
• Format: Article
• Language: fre
• Subjects: Abortion, Habitual - immunology; Antiphospholipid Syndrome - complications; Antiphospholipid Syndrome - drug therapy; Aspirin - administration & dosage; Drug Therapy, Combination; Female; Heparin - administration & dosage; Humans; Pregnancy; Pregnancy Complications - drug therapy; Pregnancy Complications - immunology; Pregnancy Outcome
• ISSN: 2468-7189
• DOI: 10.1016/j.gofs.2016.12.010

Obstetrical APS is defined by thrombosis and/or obstetrical morbidity associated with persistent antiphospholipid antibodies. The aspirin and low molecular weighted heparin combination dramatically improved obstetrical outcome in APS patients. Several factors could be associated with obstetrical prognosis, as previous history of thrombosis, associated SLE, the presence of lupus anticoagulant and triple positivity of antiphospholipid antibodies. Obstetrical APS with isolated recurrent miscarriages is mostly associated with isolated anticardiolipids antibodies and have better obstetrical outcome. The pregnancy loss despite aspirin and heparin combination define the refractory obstetrical APS, and the prevalence could be estimated to 20-39%. Several other treatments have been used in small and open labeled studies, as steroids, intravenous immunoglobulins, plasma exchanges and hydroxychloroquine to improve the obstetrical outcome. Some other drugs as eculizumab and statins could also have physiopathological rational, but studies are necessary to define the place of these various drugs.